Predicting drug interactions in vivo from experiments in vitro: Human studies with paclitaxel and ketoconazole

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 20, Issue 6, 1997, Pages 592-599

  Jamis Dow, Carlos A ^a   Pearl, Michael L ^b   Watkins, Paul B ^b   Blake, Debbie S ^b   Klecker, Raymond W ^a   Collins, Jerry M ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

CYP3A; Drug metabolism; Erythromycin breath test

Indexed keywords

CYTOCHROME P450; KETOCONAZOLE; PACLITAXEL;

ARTICLE; BREATH ANALYSIS; CLINICAL ARTICLE; DIAGNOSTIC VALUE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MINIMUM INHIBITORY CONCENTRATION; OVARY CANCER; PREDICTION;

ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ARYL HYDROCARBON HYDROXYLASES; BREATH TESTS; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ERYTHROMYCIN; FEMALE; HUMANS; KETOCONAZOLE; OVARIAN NEOPLASMS; OXIDOREDUCTASES, N-DEMETHYLATING; PACLITAXEL;

EID: 0030696112     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199712000-00013     Document Type: Article

References (27)

1. Wani MC, Taylor HL, Wall ME, et al. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971;93:2325-7.
2. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995;332:1004-14.
3. Kumar GN, Walle UK, Walle T. Cytochrome P450 3A-mediated human liver microsomal taxol 6 alpha-hydroxylation. J Pharmacol Exp Ther 1994;268:1160-5.
4. Harris JW, Katki A, Anderson LW, Chmurny GN, Paukstelis JV, Collins JM. Isolation, structural determination, and biological activity of 6 alpha-hydroxytaxol, the principal human metabolite of taxol. J Med Chem 1994;37:706-9.
5. Cresteil T, Monsarrat B, Alvinerie P, Treluyer JM, Vieira I, Wright M. Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res 1994;54:386-92.
6. Rahman A, Korzekwa KR, Grogan J, etal. Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 1994;54:5543-6.
7. Maurice M, Pichard L, Daujat M, et al. Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB J 1992;6:752-8.
8. Jamis-Dow CA, Klecker RW, Katki AG, Collins JM. Metabolism of taxol by human and rat liver in vitro: a screen for drug interactions and interspecies differences. Cancer Chemother Pharmacol 1995;36:107-14.
9. Daneshmend TK, Warnock DW. Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet 1988;14:13-34.
10. Watkins PB, Murray SA, Winkelman LG, et al. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients. J Clin Invest 1989;83:688-97.
11. Cragg GM, Snader KM. Taxol: the supply issue. Cancer Cells 1991;3:233-5.
12. Rowland M, Towzer TN. Clinical Pharmacokinetics. Concepts and Applications. 2nd ed. Philadelphia: Lea & Febiger 1989:459-61.
13. 2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer. Cancer Chemother Pharmacol 1993;33:48-52.
14. Klecker RW, Jamis-Dow CA, Egorin MJ, et al. Effect of cimetidine, probenecid, and ketoconazole on the distribution, biliary secretion, and metabolism of [3H]taxol in the Sprague-Dawley rat. Drug Metab Dispos 1994;22:254-8.
15. The Merck Index Eleventh Edition, Rahway, NJ: Merck & Co, Inc, 1989.
16. Reed E, Sarosy G, Jamis-Dow C, et al. Cimetidine does not influence taxol steady-state plasma levels. Proc Am Assoc Cancer Res 1993;34:395.
17. Slichenmyer WJ, Donehower RC, Chen TL, et al. Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia. Cancer Chemother Pharmacol 1995;36:227-32.
18. Monsarrat B, Alvinerie P, Wright M, et al. Hepatic metabolism and biliary excretion of Taxol in rats and humans. J Natl Cancer Inst Monogr 1993;15:39-46.
19. Eiseman JL, Eddington ND, Leslie J, et al. Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. Cancer Chemother Pharmacol 1994;34:465-71.
20. Sparreboom A, van Tellingen O, Nooijen WJ, et al. Tissue distribution, metabolism and excretion of paclitaxel in mice. Anticancer Drugs 1996;7:78-86.
21. Hoener BA. Predicting the hepatic clearance of xenobiotics in humans from in vitro data. Biopharm Drug Dispos 1994; 15:295-304.
22. Houston JB. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 1994;47:1469-79.
23. Harris JW, Rahman A, Kim BR, et al. Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 1994;54:4026-35.
24. Holton RA, Somoza C, Kim HB, et al. First total synthesis of taxol. 1. Functionalization of the B ring. J Am Chem Soc 1994;116:1597-8.
25. Holton RA, Kim HB, Somoza C, et al. First total synthesis of taxol. 2. Completion of the C and D rings. J Am Chem Soc 1994;116:1599-1600.
26. Nicolaou KC, Yang Z, Liu JJ, et al. Total synthesis of taxol. Nature 1994;367:630-4.
27. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, et al. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J Pharmacol Exp Ther 1994;268:1278-83.